(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 180.6MM | - |
Operating Income | -46MM | +45% |
Operating Expenses | 226.6MM | - |
Net Income | -36.4MM | +23% |
R&D | 31.4MM | - |
G&A | 44.8MM | - |
Marketing | 51.4MM | - |
Amortization | 9.9MM | +85% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
SOUTH SAN FRANCISCO, Calif., February 27, 2024--Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines.
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet. To mitigate the downside risks, it may be better to consider undervalued enterprises. Of course, specifically targeting biotech stocks that trade below their intrinsic or perceived value offers no guarantee of success. Still, given the sometimes extreme mobility that the ecosystem facilitates, it may pa
Veracyte ( NASDAQ:VCYT ) Full Year 2023 Results Key Financial Results Revenue: US$361.1m (up 22% from FY 2022). Net...
Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript February 22, 2024 Veracyte, Inc. misses on earnings expectations. Reported EPS is $-0.39 EPS, expectations were $-0.07. Veracyte, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you […]
Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.
Q4 2023 Veracyte Inc Earnings Call
Veracyte (VCYT) delivered earnings and revenue surprises of 42.86% and 2.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Full-Year Revenue Hits $361.1 Million Amidst Expansion and Innovation in Diagnostic Offerings
SOUTH SAN FRANCISCO, Calif., February 22, 2024--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023.
SOUTH SAN FRANCISCO, Calif., February 21, 2024--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and John Leite, Ph.D., chief commercial officer, CLIA, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024, at 9:50 a.m. Eastern Time.